Document is current
Any future updates will be listed below
-
Authors
Yousif, Laura I.
Sijtema, Aukje G.
Appels, Ymke
Screever, Elles M.
van Blokland, Irene V.
Oelen, Roy
Groot, Hilde E.
Gergely, Tamás G.
Kocsis, Márton
Leszek, Przemyslaw
Varga, Zoltán V.
Aboumsallem, Joseph Pierre
der Harst, Pim van
Franke, Lude H.
van der Wijst, Monique G. P.
de Boer, Rudolf A.
Lipšic, Erik
Meijers, Wouter C. https://orcid.org/0000-0002-3287-6766
-
Funding
Funding for this research was provided by:
Dutch Research Council
- License Information
-
More Information
Article History
Received: 21 December 2024
Accepted: 14 May 2025
First Online: 27 June 2025
Change Date: 26 September 2025
Change Type: Update
Change Details: In this article, the Funding reference ID was omitted in the metadata. This has now been updated.
Competing interests
: L.H.F. is supported by a grant from the Dutch Research Council (ZonMW-VICI 09150182010019 to L.H.F.), and a sponsored research collaboration with Biogen, Roche and Takeda. This work is co-financed by Oncode Institute, which is partly funded by the Dutch Cancer Society. This project has received funding from the European Union’s Horizon Europe research and inno-vation program under grant agreement No 101057553. M.G.P.v.d.W. is supported by a grant from the Dutch Research Council (NWO-VIDI 223.041 to M.G.P.v.d.W.). R.A.d.B is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). R.A.d.B has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, Cardior Pharmaceuticals GmbH, NovoNordisk, and Roche and travel support from Abbott, Cardior Pharmaceuticals GmbH, and Novo-Nordisk. W.C.M. is supported by grants from the Dutch Heart Foundation (Dekkerbeurs 03–005-2021-T005) and grants from ZonMW (Off Road; 04510012210034 & VENI; 09150162310159). W.C.M. has received speaker/ advisory board fees from Daiichi Sankyo and Novartis.
